Desiree Matthews, PMHNP-BC reviews the AIMS and other assessment instruments—what to use and when.
Supported by an educational grant from Neurocrine Biosciences, Inc.
All Podcasts
Desiree Matthews, PMHNP-BC provides a clinical guide to distinguishing these movement disorders.
Desiree Matthews, PMHNP-BC gives a brief, clinical overview of the prevalence, symptoms, and diagnostic criteria for TD.
Desiree Matthews, PMHNP-BC, discusses what realistic treatment outcomes look like and how to talk about them with patients.
Jonathan Meyer, MD discusses age, sex, duration of treatment, comorbidities, and other risk factors.
Jonathan Meyer, MD discusses subtle movements that are easy to overlook and how to recognize them early.
Jonathan Meyer, MD compares first-generation and second-generation antipsychotics in TD risk.
Dr. Meyer discusses how dopamine receptor changes contribute to the development of tardive dyskinesia and the potentially detrimental effects of some treatments.
Hello colleagues, welcome to this podcast. Today, we'll discuss "Beyond the Side Effects: Understanding and Addressing Tardive Dyskinesia." Our focus will be on helping healthcare providers recognize the persistence and pathophysiology of tardive dyskinesia and differentiate it from common medication side effects.
Welcome back, colleagues, to our discussion on the hidden toll of tardive dyskinesia beyond movement symptoms. I look forward to exploring this topic, as it reflects my over 30 years in the field and my initial unawareness of the broader impact of tardive dyskinesia.